

	<b>HEMATOLOGY PROGRAM</b>	
	<b>17 OCTOBER 2018</b>	
13.00 - 13.15	<b>OPENING REMARKS - Birol Güvenç - Giuseppe Saglio</b>	
	<b>SESSION I - PROF. ELIEZER RACHMILEWITZ SESSION</b>	<b>CHAIRS: Osman İlhan, Serdar Bedii Omay</b>
13.15 - 13.25	How Hematology Changed During the Days in the Life of Eliezer Rachmilewitz	Giuseppe Saglio
13.25 - 13.45	Lessons Learned From CML (Inaugural Lecture Dedicated to Eliezer Rachmilewitz)	Robert Gale
13.45 - 14.05	Von Willebrand Disease, Laboratory Issues	Pierre Toulon
14.05 - 14.25	Tumor Evolution in Genomic Era and Darwin	Emin Kansu
14.25 - 14.45	The Role of T Cell Immunotherapy in the Management of Aggressive Lymphomas	Hanan Hamed
14.45 - 15.00	Best Abstract Presentation (Eliezer Rachmilewitz Price) - Analysis of Genetic Abnormalities in Newly	Osamah Khojah
15.00 - 15.30	<b>COFFEE BREAK</b>	
	<b>SESSION II - PROF. EKREM MÜFTÜOĞLU SESSION - MYELODYSPLASTIC SYNDROME</b>	<b>CHAIRS: Tapan Kadia, Zahit Bolaman, Orhan Ayyıldız</b>
15.30 - 16.00	Paroxysmal Nocturnal Hemoglobinuria	Hanan Hamed
16.00 - 16.30	Prognostic Molecular Markers in MDS	Mustafa Çetiner
16.30 - 17.00	Current Treatment of MDS	Tapan Kadia
17.00 - 17.30	New Therapies in MDS	Tapan Kadia

17.30 - 18.00	COFFEE BREAK	
	SESSION III - PROF. ATILLA YALÇIN SESSION - CHRONIC MYELOPROLIFERATIVE DISORDERS	CHAIRS: Tariq Mughal, Ferit Avcu, Fahri Şahin
18.00 - 18.30	Current Treatment of Myeloproliferative Neoplasms	Haifa Kathrin Al-Ali
18.30 - 19.00	Jak2 Inhibitors and What Comes Next for Patients with BCR-ABL1- Negative Myeloproliferative Neoplasms	Tariq Mughal
19.00 - 19.30	Molecular Markers and New Prognostic Scores in MPNs	Tariq Mughal
19.30 - 20.30	POSTER PRESENTATIONS SESSION 1	CHAIRS: Ahmet İfran, Ahmet Öztürk, Ozan Salim

	<b>18 OCTOBER 2018</b>	
07.30 - 08.15	<b>MEET THE EXPERT SESSION &amp; ORAL PRESENTATIONS - ROOM 1 - Angelo Maiolino (MM) / ROOM 2 - Tapan Kadia (MDS) / ROOM 3 - Nitin Jain (ALL) - Chairs: Emin Kaya, Mahmut Töbü, Pervin Topçuoğlu</b>	
	<b>SESSION IV - MULTIPLE MYELOMA</b>	<b>CHAIRS: Angelo Maiolino, Levent Ündar</b>
08.30 - 09.00	First Line Therapy for Multiple Myeloma	Guray Saydam
09.00 - 09.30	Treatments in Relapsed / Refractory Multiple Myeloma	Angelo Maiolino
09.30 - 10.00	New Drugs for Multiple Myeloma	Angelo Maiolino

10.00 - 10.30	<b>COFFEE BREAK</b>	
	<b>SESSION V - ACUTE MYELOID LEUKEMIA</b>	<b>CHAIRS: Alessandro Cignetti, Seçkin Çağırğan, Osman Özcebe</b>
10.30 - 11.00	AML Therapy: What is Essential and What is Investigational	Tapan Kadia
11.00 - 11.30	Molecular Characterization and Follow Up in AML, Practical Issues	Mehmet Yılmaz
11.30 - 12:00	APL: A Special Kind of AML with a Different Treatment	Alessandro Cignetti

12.00 - 13.00	<b>LUNCH BREAK</b>	
---------------	--------------------	--

13.00 - 13.45	Significant Milestones in CML Treatment - NOVARTIS SATELLITE	<b>Chair:</b> Birol Güvenç <b>Speaker:</b> Güray Saydam
---------------	--	---

	<b>SESSION VI - ACUTE LYMPHOID LEUKEMIAS</b>	<b>CHAIR: Dieter Hoelzer, Deniz Sargin, Mustafa Yenerel</b>
13.45 - 14.15	ALL Therapy: Essential Elements for Proper Treatment	Dieter Hoelzer

14.15 - 14.45	Diagnostic And Prognostic Markers in ALL	Robin Foà
14.45 - 15.15	New Monoclonal Antibodies in ALL	Nitin Jain
15.15 - 15.35	Debate: Ph-Positive Acute Lymphoblastic Leukemia: Will We Still Need Chemotherapy and Stem cell Transplantation? Yes	Dieter Hoelzer
15.35 - 15.55	Debate: Ph-Positive Acute Lymphoblastic Leukemia: Will We Still Need Chemotherapy and Stem cell Transplantation? No	Robin Foà
15:55 - 16:30	COFFEE BREAK	
	SESSION VII - HEMATOLOGY SPECIALIST ASSOCIATION - HELLENIC SOCIETY OF HEMATOLOGY JOINT SESSION	CHAIRS: Panayiotis Panayiotidis, Birol Güvenç, Sehmus Ertop
16.30 - 17.00	New Therapeutic Options in CLL?	Panayiotis Panayiotidis
17.00 - 17.30	New Biomarkers in CLL?	TBA
17.30 - 18.00	Future Goals in CLL Therapy	Robin Foà

18.00 - 19.00	POSTER PRESENTATIONS SESION 2	CHAIRS: Oktay Bilgir, Sami Kartı, İsmet Aydoğdu
	<b>19 OCTOBER 2018</b>	
07.30 - 08.15	ON & ORAL PRESENTATIONS - ROOM 1 - Carmino de Souza (NHL) / ROOM 2 - Tariq Mughal (CMD) / ROOM 3 - Dieter Hoelzer (ALL) Chairs: Gülsüm Özet, Atıl	
	SESSION VIII - APHERESIS SESSION	CHAIRS: Robert Weinstein, Fevzi Altuntaş
08.30 - 09.00	Apheresis in the Management of Hematological Disorders Using the Therapeutic Apheresis Guidelines of the American Society for Apheresis	Joseph Schwartz
09.00 - 09.30	Medical Decision Making in Apheresis Medicine: When the Guidelines Do Not Cover Your Patient's Condition	Robert Weinstein
09.30 - 10.00	Recent Advances in the Management of Thrombotic Thrombocytopenic Purpura (TTP) and Their Effect on the Role of Apheresis in Its Treatment	Ravi Sarode
10.00 - 10.30	<b>COFFEE BREAK</b>	
	SESSION IX - CHRONIC MYELOID LEUKEMIAS	CHAIRS: Rudiger Hehlmann , Ridvan Ali, Burhan Turgut
10.30 - 11.00	Impact of High-Risk Additional Chromosome Aberration on Survival and Blast Crisis	Rudiger Hehlmann
11.00 - 11.30	Are the Results that We Can Obtain with Imatinib All the Same in the World?	Katia Pagnano
11.30 - 12.00	Treatment Discontinuation in Chronic Myeloid Leukemia, When and How ?	Giuseppe Saglio
12:00 - 12:30	Response Monitoring in Chronic Myeloid Leukemia in the TFR Era	Naeem Chaudhri
12.30 - 13.15	New Era with Carfilzomib in the Treatment of Relapsed / Refractory Multiple Myeloma - AMGEN SA	Chair: Ali Ünal Speaker: Güray Saydam

13.15 - 14.15	<b>LUNCH BREAK</b>	
14.15 - 15.00	New Treatment Approaches in ALL Treatment - BMS SATELLITE	<b>Chair:</b> Birol Güvenç <b>Speaker:</b> Mehmet Ali Özcan
	<b>SESSION X - SPECIAL TOPICS FOR NHL</b>	<b>CHAIRS:</b> Carmino de Souza, Burhan Ferhanoğlu
15.00 - 15.30	State of the Art of NHL Therapy	Carmino de Souza
15.30 - 16.00	A Translational Perspective on Diffuse Large B-Cell Lymphoma	Yücel Erbilgin
16.00 - 16.30	New Approaches in Marginal Zone Lymphoma	Catherine Thieblemont
16.30 - 17.00	Mantle Cell Lymphoma, Blastic Variant; Diagnosis, Treatment	Tayfur Toptaş
17.00 - 17.30	<b>COFFEE BREAK</b>	
	<b>SESSION XI - AGGRESSIVE AND INDOLENT NH LYMPHOMAS</b>	<b>CHAIRS:</b> Catherine Thieblemont, Tayfur Toptaş
17.30 - 18.00	Essential Treatments of NHL	Carmino de Souza
18.00 - 18.30	First-Line Treatment of Hodgkin Lymphoma	Massimo Federico
18.30 - 19.00	Transplant in NHL; When? To Whom?	Elif Birtaş Ateşoğlu
19.00 - 20.00	<b>POSTER PRESENTATIONS SESION 3</b>	<b>CHAIRS:</b> Oral Nevruz, Ihsan Karadoğan, Güven Cetin
	<b>20 OCTOBER 2018</b>	

07.30 - 08.15	<b>MEET THE EXPERT SESSION &amp; ORAL PRESENTATIONS - ROOM 1 - Panayiotis Panayiotidis (CLL) / ROOM 2 - Massimo Federico (NHL) / ROOM 3 - Alessandro Cignetti (AML) Chairs: Salih Aksu, Cengiz Ceylan, Mehmet Sönmez</b>	
	<b>SESSION XII- CHRONIC LYMPHOCYTIC LEUKEMIAS AND INDOLENT LYMPHOMAS</b>	<b>CHAIRS: Mehmet Turgut, Hakan Göker, Nilgün Sayinalp</b>
08.30 - 09.00	CLL Treatment Landscape in R/R CLL Patients in Scope of BCL-2 Inhibition	Mehmet Ali Özcan
09.00 - 09.30	Chronic Lymphocytic Leukemia Old and New Treatments	Panayiotis Panayiotidis
09.30 - 10.00	When and Why Chemo-Free Regimens in Mantle Cell Lymphoma	Burhan Ferhanoğlu

10.00 - 10.30	<b>COFFEE BREAK</b>	
	<b>SESSION XIII - STEM CELL TRANSPLANT AND CELLULAR THERAPY</b>	<b>CHAIRS: Jean-Francois Rossi, Filiz Vural</b>
10.30 - 11.00	Cancer Immunotherapy: Monoclonal antibodies from laboratory reagents to therapy	Vera Donnerberg
11.00 - 11.30	Single cell surface proteomics for discovery of therapeutic targets	Albert Donnerberg
11.30 - 12.00	Impact of Posttransplant Hypomethylating Agents on Cumulative Incidence Risk of Relapse After Allogeneic Transplants for Myeloid Malignancies	Khalid Halahleh
12.00 - 12.30	From Allogeneic Transplantation to Precision Immune Therapy: The Role of Effector Cells	Jean-Francois Rossi
12.30 - 13.00	Antifungal Management in Febrile Neutropenia	Ömür Uzun
13.00	<b>CLOSING</b>	